Structural requirements for the activation of human factor VIII by thrombin

Blood

Volumn 100, Issue 8, 2002, Pages 2820-2826

  Myles, Timothy ^a   Yun, Thomas H ^a   Leung, Lawrence L K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; THROMBIN;

ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD VESSEL INJURY; ENZYME ACTIVE SITE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 0037108447     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0843     Document Type: Article

References (57)

1. Kane WH, Davies DW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71:539-555.
2. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A. 1987;84: 4846-4850.
3. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342.
4. Ortel TL, Takahashi N, Putnam FW. Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains. Proc Natl Acad Sci U S A. 1984;81:4761-4765.
5. Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature. 1999;402:434-439.
6. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 1999;402:439-442.
7. Shima M, Nakai H, Scandella D, et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Hematol. 1995;91:714-721.
8. Saenko EL, Shima M, Rajalakshmi KL, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem. 1994; 26:11601-11605.
9. Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg 1689. J Biol Chem. 2000;275:25774-25780.
10. Nogami K, Shima M, Hosokawa, K, et al. A role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000-31007.
11. Esmon CT. The subunit structure of thrombin-activated factor V: isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem. 1979;254:964-973.
12. Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982;257:6556-6564.
13. Thorelli E, Kaufman RJ, Dahlback B. Cleavage requirements for activation of factor V by factor Xa. Eur J Biochem. 1997;247:12-20.
14. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature. 1984;312:342-347.
15. Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol. 1993;222:128-143.
16. Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A. 1988;85:2429-2433.
17. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem. 1990;265: 17854-17858.
18. Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem. 1995;270:8546-8552.
19. Gitschier J, Kogan S, Levinson B, Tuddenham ED. Mutations of factor VIII cleavage sites in hemophilia A. Blood. 1988;72:1022-1028.
20. Hofsteenge J, Stone SR. The effect of thrombomodulin on the cleavage of fibrinogen and fibrinogen fragments by thrombin. Eur J Biochem. 1987; 168:49-56.
21. Hofsteenge J, Braun PJ, Stone SR. Enzymatic properties of proteolytic derivatives of human alpha-thrombin. Biochemistry. 1988;27:2144-2151.
22. Binnie CG, Lord ST. The fibrinogen sequences that interact with thrombin. Blood. 1993;81:3186-3192.
23. Liu LW, Vu TKH, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem. 1991;266:16977-16980.
24. Mathews II, Padmanabhan KP, Ganesh V, et al. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry. 1994;33:3266-3279.
25. Myles T, Le Bonniec BF, Stone SR. The dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1. Eur J Biochem. 2001;268:70-77.
26. Hofsteenge J, Taguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem J. 1986;237:243-251.
27. Henricksen RA, Mann KG. Identification of the primary structural defect in the dysthrombin thrombin Quick I: substitution of cysteine for arginine-382. Biochemistry. 1988;27:9160-9165.
28. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LLK, Gibbs CS. Functional mapping of the surface residues of human thrombin. J Biol Chem. 1995;270:16854-16863.
29. Sheehan JP, Wu Q, Tollefson DM, Sadler JE. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III: interaction with the anion-binding exosite determines heparin cofactor II specificity. J Biol Chem. 1993;268:3639-3645.
30. Sheehan JP, Tollefson DM, Sadler JE. Heparin cofactor II is regulated allosterically and not primarily by template effects: studies with mutant thrombins and glycosaminoglycans. J Biol Chem. 1994;269:32747-32751.
31. Myles T, Church FC, Whinna HC, Monard D, Stone SR. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. J Biol Chem. 1996;273:31203-31208.
32. Stone SR, Braun PJ, Hofsteenge J. Identification of regions of alpha-thrombin involved in its interaction with hirudin. Biochemistry. 1987;26:4617-4624.
33. Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 1990;249: 277-280.
34. Myles T, Le Bonniec BF, Betz A, Stone SR. Electrostatic steering and ionic tethering in the formation of thrombin-hirudin complexes: the role of the thrombin anion-binding exosite-I. Biochemistry. 2001;40:4972-4979.
35. Wallace A, Rovelli G, Hofsteenge J, Stone SR. Effect of heparin on the glia-derived-nexin-thrombin interaction. Biochemical J. 1989;257:191-196.
36. Stone SR, Brown-Leudi ML, Rovelli G, Guidolin A, McGlynn E, Monard D. Localization of the heparin-binding site of glia-derived nexin/protease nexin-1 by site-directed mutagenesis. Biochemistry. 1994;33:7731-7735.
37. Li CQ, Vindigni A, Sadler JE, Wardell MR. Platelet glycoprotein Ib alpha binds to thrombin anionbinding exosite II inducing allosteric changes in the activity of thrombin. J Biol Chem. 2001;276: 6161-6168.
38. Cristofaro R, De Candia E, Landolfi R, Rutella S, Hall SW. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry. 2001;40: 13268-13273.
39. Richardson JL, Kroger B, Hoeffken W, et al. Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. EMBO J. 2000;19:5650-5660.
40. Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem. 1996;271: 13882-13887.
41. + binding site of thrombin. J Biol Chem. 1995;270: 22089-22092.
42. Myles T, Yun TH, Hall SW, Leung LLK. An extensive interaction interface between thrombin and factor V is required for factor V activation. J Biol Chem. 2001;276:25143-25149.
43. Hall SW, Nagashima M, Zhao L, Morser J, Leung LLK. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem. 1999;274:25510-25516.
44. Bode W, Turk D, Karshikow A. The refined 1.9-A x-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry and structure function relationships. Protein Sci. 1992;1:426-471.
45. Di Cera E, Dang QD, Ayala YM. Molecular mechanisms of thrombin function. Cell Mol Life Sci. 1997;53:701-730.
46. Fuentes-Prior P, Iwanaga Y, Huber R, et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 2000;404:518-525.
47. Fuentes-Prior P, Noeske-Jungblut C, Donner P, Schleuning WD, Huber R, Bode W. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc Natl Acad Sci U S A. 1997;94:11845-11850.
48. van de Locht A, Stubbs MT, Bode W, et al. The ornithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J. 1996;15:6011-6017.
49. van de Locht A, Lamba D, Bauer M, et al. Two heads are better than one: crystal structure of the insect-derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J. 1995;14:5149-5157.
50. Saenko EL, Scadella D. The acidic region of the factor VIII light chain and the C2 domain together form the high-affinity binding site for von Willebrand factor. J Biol Chem. 1997;272:18007-18014.
51. Arni RK, Padmanabhan K, Padmanabhan KP, Wu TP, Tulinsky A. Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin. Biochemistry. 1993;32:4727-4737.
52. Tsaing M, Jain AK, Gibbs CS. Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. J Biol Chem. 1997;272:12024-12029.
53. Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature. 1995;378:413-416.
54. Tsiang M, Paborsky LR, Li WX, et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry. 1996;35:16449-16457.
55. Tsiang M, Gibbs CS, Griffin LC, Dunn KE, Leung LLK. Selection of a suppressor mutation that restores affinity of an oligonucleotide inhibitor for thrombin using in vitro genetics. J Biol Chem. 1995;270:19370-19376.
56. Krishnan R, Sadler JE, Tulinsky A. Structure of the Ser195Ala mutant of human alpha-thrombin complexed with fibrinopeptide A(7-16): evidence for residual catalytic activity. Acta Crystallogr D Biol Crystallogr. 2000;56:406-410.
57. Guinto ER, Di Cera E. Critical role of W60d in thrombin allostery. Biophys Chem. 1997;64:103-109.